Sulfonylureas target the neurovascular response to decrease Alzheimer's pathology

Shannon L. Macauley^{1,2,4,5,6,8,9*}, Molly S. Stanley⁹, Emily E. Caesar⁹, William R. Moritz⁹, Annie R. Bice¹⁰, Nildris Cruz-Diaz^{3,7,8}, Caitlin M. Carroll¹, Stephen M. Day^{1,2}, John Grizzanti¹, Thomas E. Mahan⁹, James A. Snipes¹, Timothy E. Orr¹, Joseph P. Culver^{10,12}, Maria S. Remedi¹⁴, Colin G. Nichols¹⁴, Celeste M. Karch^{11,12,13}, Laura A. Cox^{1,5}, Debra I. Diz^{3,7,8}, Adam Q. Bauer¹², and David M. Holtzman^{9,12,13}

Department of Internal Medicine¹, Physiology and Pharmacology², Surgery³, Alzheimer's Disease Research Center⁴, Center for Diabetes and Metabolism⁵, Center for Precision Medicine⁶, Hypertension & Vascular Research Center⁷, Cardiovascular Sciences Center⁸, Wake Forest School of Medicine, Winston Salem, NC 2710; Department of Neurology⁹, Radiology¹⁰, Psychiatry¹¹, the Hope Center for Neurological Disorders¹², Charles F. and Joanne Knight Alzheimer's Disease Research Center¹³, and Center for Excitability and Membrane Disorders¹⁴, Washington University School of Medicine, St. Louis, Missouri 63110;

***corresponding author**

Corresponding author:

Shannon L. Macauley, PhD

Assistant Professor

Department of Internal Medicine - Gerontology & Geriatric Medicine

575 N. Patterson Ave.

Winston-Salem, NC 27101

email: smacaule@wakehealth.edu

phone: 336.716.4628

The authors have declared that no conflict of interest exists.

Graphical abstract. Targeting vascular K_{ATP} channel activity for the treatment of Alzheimer's disease pathology.

Alzheimer's Disease

$\uparrow A\beta$ aggregation
 $\uparrow$ hyperexcitability
 $\uparrow$ vascular K_{ATP} channels
 $\uparrow$ vascular remodeling
 $\uparrow$ arterial stiffness
 $\uparrow$ cognitive deficits

Glyburide Treatment

$\downarrow$ amyloid plaques
 $\downarrow$ hyperexcitability
 $\downarrow$ vascular damage
 $\downarrow$ arterial stiffness
 $\downarrow$ cognitive deficits

ABSTRACT

Hyperexcitability is a defining feature of Alzheimer's disease (AD), where aberrant neuronal activity is both a cause and consequence of AD. Therefore, identifying novel targets that modulate cellular excitability is an important strategy for treating AD. ATP-sensitive potassium (K_{ATP}) channels are metabolic sensors that modulate cellular excitability. Sulfonylureas are K_{ATP} channel antagonists traditionally used to combat hyperglycemia in diabetic patients by inhibiting pancreatic K_{ATP} channels, thereby stimulating insulin release. However, K_{ATP} channels are not limited to the pancreas and systemic modulation of K_{ATP} channels has pleotropic physiological effects, including profound effects on vascular function. Here, we demonstrate that human AD patients have higher cortical expression of vascular K_{ATP} channels, important modulators of vasoreactivity. We demonstrate that peripheral treatment with the sulfonylurea and K_{ATP} channel inhibitor, glyburide, reduced the aggregation and activity-dependent production of amyloid-beta ($A\beta$), a hallmark of AD, in mice. Since glyburide does not readily cross the blood brain barrier, our data suggests that glyburide targets vascular K_{ATP} channel activity to reduce arterial stiffness, improve vasoreactivity, and normalize pericyte-endothelial cell morphology, offering a novel therapeutic target for AD.

Word count: 179

INTRODUCTION

Normal cellular excitability underlies physiological function and when altered, can lead to or exacerbate disease. Brain hyperexcitability is central to the pathophysiology of Alzheimer's disease, with aberrant neuronal activity is both a cause and consequence of Alzheimer's pathology. Neuronal release of amyloid- β ($A\beta$) and tau, the pathological hallmarks of AD, is driven by changes in neuronal activity [1-7]. Neurons generate soluble, monomeric $A\beta$ via the sequential cleavage of the amyloid precursor protein (APP) and secrete $A\beta$ into the extracellular space [8, 9]. $A\beta$ release at the synapse occurs in an activity dependent manner, whereby increased activity raises interstitial fluid (ISF) $A\beta$ levels, which can then form toxic, higher order species and aggregate into amyloid plaques in a concentration-dependent manner [1, 2, 10, 11]. Thus, increasing neuronal excitability will increase extracellular $A\beta$ release and promote plaque formation in the brain. Similarly, targeting aberrant excitability could mitigate $A\beta$ release and amyloid plaque development.

Widely distributed in excitable cells, ATP-sensitive potassium (K_{ATP}) channels link changes in metabolism with electrical activity [12, 13]. In pancreatic beta cells, K_{ATP} channels close in response to rising blood glucose levels, triggering insulin secretion. K_{ATP} channels are also expressed in multiple neuronal subtypes. Our previous studies demonstrate that pharmacological manipulation of neuronal K_{ATP} channels altered neuronal excitability and ISF $A\beta$ levels [7]. This work echoed previous findings that increased cerebral metabolism promotes neuronal K_{ATP} channel closure and increased excitability [14-16]. In vascular smooth muscle cells, K_{ATP} channels regulate blood flow, vasodilation/vasoconstriction, and vascular tone [12, 17, 18]. Since hyperexcitability is a key feature of AD, we hypothesized that changes in K_{ATP} channel activity at the neurovascular unit can alter neuronal activity and AD pathogenesis, and hence, serve as a therapeutic target in AD.

Epidemiological studies suggest that sulfonylureas, a class of FDA approved drugs that inhibit K_{ATP} channel activity [19], may reduce AD and dementia risk, but the mechanisms are unknown [20-22]. To date, no prospective study in humans has evaluated the effects of sulfonylureas on vascular health, brain function, or cognition, in AD. Interestingly, sulfonylureas are widely used to treat type 2 diabetes, a risk factor for AD [23], and currently being assessed in preclinical and clinical studies for other CNS diseases, including stroke and traumatic brain injury [24-27].

The goal of this work was to elucidate the role of vascular K_{ATP} channels in AD and determine whether K_{ATP} channel inhibition with glyburide could alter AD pathogenesis. We find that K_{ATP} channel subunits localized to vascular smooth muscle cells, endothelial cells, and/or pericytes are upregulated in human AD brains. Using an established model of cerebral amyloidosis, the APP^{swe}/PSEN1^{dE9} (APP/PS1) mouse [28], we demonstrate that peripheral administration of the sulfonylurea glyburide decreased amyloid burden and altered stimulus-driven neural and hemodynamic activity. Consistent with $A\beta$ being released in an activity dependent manner, we further demonstrate that decreased evoked responses lead to decreased hippocampal ISF $A\beta$ levels. Ultimately, these reductions were associated with decreased $A\beta$ aggregation. Given that glyburide does not efficiently cross the blood-brain barrier (BBB) [29] and that vascular K_{ATP} channels regulate vasoreactivity, we explored whether glyburide treatment impacted cerebrovascular morphology and function. In mice, glyburide altered the neurovascular response, reduced arterial stiffness, and normalized pericyte-endothelial cell morphology. Short

term glyburide treatment also improved learning and memory in APP/PS1 mice. Taken together, these data suggest that K_{ATP} channels not only play a critical and previously unappreciated role linking A β with neurovascular dysfunction in AD, but also offer a novel therapeutic target in AD.

RESULTS

K_{ATP} channels are upregulated in human Alzheimer's disease brains. Using the publicly available database from Mayo RNAseq Study (via AMP-AD Knowledge Portal), we investigated K_{ATP} channel expression in the temporal cortex in pathological aging (PA=amyloid without tau), Alzheimer's disease (AD=amyloid and tau), and progressive supranuclear palsy (PSP=tau without amyloid) (Fig 1). *KCNJ8*, *KCNJ11*, *ABCC8*, *ABCC9* genes code for the K_{ATP} channel subunits, Kir6.1, Kir6.2, SUR1, and SUR2, respectively. At autopsy, Kir6.1 (*KCNJ8*) and SUR2 (*ABCC9*) are both significantly upregulated in AD, but not in NC, PA, or PSP. Kir6.1 and SUR2 heterodimerize to form K_{ATP} channels localized to mural cells, vascular smooth muscle cells, endothelial cells, and pericytes [30], and *ABCC9* is widely used as a transcriptional signature for pericytes [31-33]. No significant changes were observed in *KCNJ11* or *ABCC8* in any conditions (q value < 0.05). These subunits are typically enriched in neurons [34], astrocytes [35], and oligodendrocytes [16]. These results thus indicate that vascular, but not neuronal, K_{ATP} channel expression is specifically increased in human AD cortex, but not in other neurodegenerative diseases.

Systemic glyburide treatment reduces A β deposition and plaque pathology in APP/PS1 mice. Given the increased K_{ATP} channel expression in AD brains, we explored whether targeting these channels therapeutically might impact AD-related pathology. Four-month-old female APP/PS1 mice were treated with glyburide or placebo for 3 months via subcutaneous implanted slow release pellet (2.5mg/pellet; 30 μ g/day)[29, 36]. Representative images from placebo-treated mice show prominent plaque pathology in the cortex and hippocampus, but reduced A β deposition in glyburide-treated mice (Fig 2A). When quantified, A β deposition decreased by ~50% (Fig 2B) and amyloid plaques decreased by ~45% (Fig 2C) in both cortex and hippocampus. Insoluble levels of A β 40 and A β 42 decreased by ~30-40% in the hippocampus of glyburide-treated animals (Fig 2D), while soluble levels for both A β 40 and A β 42 remained unchanged. Taken together, these experiments demonstrate that systemic glyburide treatment reduces A β pathology and amyloid plaque burden.

Systemic glyburide treatment does not affect A β clearance mechanisms. While glyburide treatment reduced A β deposition, amyloid plaque pathology, and insoluble A β 40 and A β 42, it is unclear whether this was the result of decreased A β production or increased A β clearance. Therefore, we explored A β clearance mechanisms (Fig 3&4). First, we administered compound E, a potent gamma secretase inhibitor, to glyburide- or placebo-treated mice to prevent amyloid precursor protein (APP) cleavage and A β production, then quantified A β clearance from the hippocampal ISF. No difference in A β _{1-x} half-life was observed between glyburide- and placebo-treated mice (Fig 3A). There were also no differences in mRNA levels for A β degrading enzymes, insulin degrading enzyme (*Idc*) or neprilysin (*Nep*) (Fig 3B), nor in IDE protein levels. Similarly, no difference in the expression levels of clearance related proteins, such as *Apoe*, *Lrp1*, *Aqp4* or *Rage*, was detected between glyburide or placebo groups (Fig 3C).

Upregulation of the neuroinflammatory milieu, in particular astrocyte and microglial activation, also serves as a potential clearance mechanism for A β , and typically co-varies with amyloid plaque deposition. Therefore, glyburide- and placebo-treated brains were immunostained for GFAP and CD68, markers of astrocyte and microglial reactivity, respectively (Fig 4). Comparable levels of activated astrocytes (Fig 4A) and microglia (Fig 4B) were observed in the cortex and hippocampus of treated mice compared to controls at 7-months of age. Triple labeling of the mouse cortex for amyloid plaques (X34; blue), astrocytes (GFAP; green), and microglia (CD68; red) was performed to assess glial activation either proximal or distal to plaque pathology (Fig 4C). There was no difference in the total number of plaque-associated microglia nor in the number of microglia 15 μ m or 30 μ m from the plaques (Fig 4C). Similarly, at distances greater than 25 μ m from the plaques, there was no difference in the area fraction, total number, or size of activated microglia or astrocytes, suggesting comparable levels of glial activation in the glyburide- and placebo-treated mice (Fig 4D-E). Taken together, these data indicate that A β clearance pathways are unaltered in glyburide-treated mice.

Glyburide reduces activity dependent release of A β by altering the neurovascular response. A β is produced via synaptic activity, where increased neuronal activity drives A β release into the ISF [10, 37]. Therefore, we assessed activity dependent release of A β in placebo- and glyburide-treated animals, by monitoring neuronal activity, ISF A β levels, and amyloid precursor protein (APP) processing. First, EEG recordings were performed in forelimb somatosensory cortex (S1FL) during electrical stimulation of the contralateral forepaw (Fig 5). During the evoked response, the placebo group exhibited a robust (~40%) increase in EEG amplitude, while glyburide treated mice did not (~10%) (Fig 5A, B, D). Interestingly, resting state EEGs and steady state ISF lactate levels, a marker of neuronal activity, were similar between glyburide and placebo groups, suggesting that basal neuronal activity was unaffected (Fig 5C, F). Next, we investigated ISF A β levels during the resting state and after administration of picrotoxin (PTX), a GABA antagonist, to stimulate excitatory neurotransmission [1, 2, 10, 38]. Steady state levels of ISF A β were ~25% lower in the glyburide-treated group versus placebo (Fig 5E). ISF lactate, a marker of neuronal activity, increased in both the glyburide- and placebo-groups after PTX administration, confirming enhanced neuronal activity. Interestingly, PTX increased ISF A β in the placebo-, but not the glyburide-treated group (Fig 5F). This indicates that ISF A β levels were reduced by glyburide treatment during the resting state and the evoked response in APP/PS1 mice. Since PTX also induces seizures, we monitored seizure activity during the 2 hrs post-PTX administration. Although seizure number was similar between groups, there was a significant reduction in the variance in the glyburide-treated group, suggesting glyburide influenced hyperexcitability in the APP/PS1 mice. Lastly, we explored whether APP processing and A β metabolism differed between groups. APP levels were comparable between glyburide- and placebo-treated mice (Fig 5H), although there was a reduction in amyloidogenic processing of APP in the glyburide-treated. Taken together, the results indicate that systemic glyburide treatment reduces the activity dependent release of A β while preserving resting state neuronal activity.

Since glyburide does not efficiently cross the BBB [29], a direct action on neurons and glia is unlikely. Instead, we hypothesize that glyburide affects vascular K_{ATP} channel activity to alter the neurovascular response. We therefore investigated whether glyburide affected evoked hemodynamic responses in APP/PS1

mice (Fig 6). Following forepaw stimulation, both placebo- and glyburide-treated groups exhibited stimulus evoked responses consistent with functional hyperemia: increased CBF, HbO, HbT, CMRO₂ and decreased HbR (Fig 6A). However, consistent with observations from electrophysiology experiments (Fig 5B), evoked changes in CBF, HbO, and HbT due to stimulation were all significantly lower in the glyburide-treated group compared to placebo (Fig 6B). Although not significant, OEF was proportionately increased, and steady state levels of ISF glucose and ISF lactate, the two main energy substrates for the brain, were comparable between glyburide and placebo treated mice (Fig 6C). Nor was there any perturbation of peripheral metabolism with glyburide treatment, further suggesting that alterations in hemodynamic activity did not negatively affect cerebral or peripheral metabolism (Fig 6D).

Given the differences in hemodynamic activity observed between groups, we explored the possibility that glyburide treatment might cause vascular remodeling in the APP/PS1 brain. Since K_{ATP} channels are found throughout the vasculature, including endothelial cells and pericytes, we explored whether glyburide affected pericyte-endothelial cell morphology (Fig 7). Staining with CD31 (endothelial cells) and CD13 (pericytes) demonstrated that CD31 and CD13 were upregulated in the cortex of 7-month-old APP/PS1 compared to WT controls. Interestingly, glyburide-treatment of APP/PS1 mice reduced CD31 and CD13 staining, similar to WT levels (Fig 7C). Vessel diameter and width were increased in APP/PS1 mice, but this effect was reversed in glyburide treated mice (Fig 7C). This suggests that chronic treatment with glyburide prevents vascular remodeling caused by A β pathology.

Glyburide treatment reverses canonical pathways associated with vessel hypertrophy and cellular excitability. Microarray analysis of gene expression was performed on cortical tissue extracted from APP/PS1 and WT mice following glyburide or placebo treatment to assess disease- or treatment-specific changes (Figure 8). First, differentially expressed genes (DEGs) were identified using Bayesian statistics; significant genes were filtered out by a p value < 0.05, FDR-q < 0.05, and a fold-change $\geq$ 2. We found 1576 genes were differentially expressed in APP/PS1 brains compared to WT, with 851 genes upregulated and 725 genes downregulated. In the glyburide-treated APP/PS1 group compared to placebo treated APP/PS1 group, 341 genes were differentially expressed, with 161 genes being upregulated and 180 genes being downregulated (Figure 8A). 32 genes were differentially expressed in APP/PS1 v WT mice and reverse in glyburide-treated v placebo-treated APP/PS1 mice (Figure 8A). Of those 32 DEGs, 23 DEGs had known gene names (Figure 8B). The 23 DEGs were enriched for pathways including regulation of G protein-coupled receptor activity and signal transduction (e.g. *Ffar4*, *Ect2l*, *Tas2r138*, *Vmn1r234*, *Lpcat2*), protein modification and proteolysis (e.g. *Adam18*, *Metap1d*, *Pcsk5*, *Pld5*, *Zar1*), gene expression (e.g. *Dnase1l1*, *Ddmt3a*, *Nova1*), redox reactions (e.g. *Aox4*, *Iyd*), immune responses (e.g. *Cd4*, *Spn*), lipid metabolism (e.g. *Lpcat2*, *Ffar4*), and cytoskeleton integrity (e.g. *Mld1*, *Nphs2*, *Pcsk5*, *Smpx*). This suggests that glyburide can target and reverse expression of DEGs. To determine whether these glyburide-targetable genes are also differentially expressed in human AD brains, we then explored whether the 23 DEGs were also differentially expressed in the cortex from human AD brains. 6 of these DEGs were confirmed in RNAseq data from control and AD brains (Mayo RNAseq AMP-AD database). These DEGs were involved in signal transduction (e.g. *FFAR4*, *ECT2L*), proteolysis (e.g. *METAP1D*, *ADAM18*), gene expression (e.g. *DNMT3A*), and redox reactions (e.g. *IYD*). Together, this

suggests that glyburide treatment reverses DEGs associated with signal transduction and excitability due to AD-related pathology.

To further clarify how the differential expression of genes related to our functional and pathological findings, we performed Ingenuity Pathway Analysis (IPA). Three main pairwise comparisons were performed to determine the effects of glyburide treatment in APP/PS1 mice: 1) APP/PS1 placebo vs. WT placebo, 2) APP/PS1 glyburide vs. APP/PS1 placebo, and 3) APP/PS1 glyburide vs. WT placebo. These three comparisons identify pathways that were aberrantly affected by disease (APP/PS1 placebo vs. WT placebo), the effects of treatment on disease (APP/PS1 glyburide vs. APP/PS1 placebo), and what pathways are reversed by treatment (meta-analysis of all 3 comparisons). First, 54 pathways were altered by genotype, with 53 showing a positive z-score, or activation, in APP/PS1 mice compared to WT (Figure 9A). Next, 18 pathways displayed a negative z-score in glyburide-treated compared to placebo-treated APP/PS1 mice. Lastly, IPA analysis of APP/PS1 glyburide-treated vs. WT placebo animals shows that 46 pathways remained altered at the transcript level following glyburide treatment in APP/PS1 compared to WT. Interestingly, we identified 3 pathways that were upregulated by disease and downregulated with glyburide treatment to WT levels, suggesting normalization of disease-associated gene expression with glyburide treatment (Figure 9B). These three pathways included: 1) Cardiac Hypertrophy Signaling, 2) $G\alpha_q$ Signaling, and 3) Type II Diabetes Mellitus Signaling (Figure 8C), consistent with the finding that glyburide may reverse vascular remodeling and dysfunction (Figures 6&7). Activation of the Cardiac Hypertrophy Signaling pathway involves G-coupled protein receptor and calcium signaling to alter hemodynamics and vascular remodeling. Consistent with this, the $G\alpha_q$ signaling pathway was also upregulated in the APP/PS1 mice and reversed by glyburide treatment. This pathway is composed of G-coupled protein receptor signaling, including the IP3-DAG-calcium pathway activated by adrenergic receptors, to mediate vasoreactivity and vessel hypertrophy which is known to be mediated by Kir channel activity [39-42]. Lastly, DEGs involved in the Type II Diabetes Mellitus (T2DM) pathway are associated with voltage gated calcium channel activity, protein kinase activity, inflammation, and apoptosis (Figure 9C).

Using the RNAseq data from control and AD brains (Mayo RNAseq AMP-AD database), we explored whether the DEGs associated with these 3 pathways were also differentially expressed in cortex from human AD brains. We identified 16 specific genes that were implicated in human AD and that were normalized by glyburide treatment in APP/PS1 mice. Of these 16 genes, DEGs were enriched in pathways involved in GPCR signaling, calcium signaling, apoptosis, inflammation, and neurotransmission (Figure 9D). Finally, 3 additional pathways were upregulated in APP/PS1 mice compared to WT and downregulated with glyburide treatment, but remained dysregulated compared to wildtype controls: 1) Role of NFAT in Cardiac Hypertrophy, 2) Corticotropin Releasing Hormone Signaling, and 3) Signaling by Rho Family GTPases. These pathways reinforce our findings that systemic glyburide treatment affects vascular K_{ATP} channel activity to impact vascular structure and function, neuronal activity, and AD-related pathology.

Glyburide treatment reverses arterial stiffness and improves learning and memory. Ingenuity pathway analysis (IPA) implicated cardiac hypertrophy and vascular remodeling as potential targets for glyburide in APP/PS1 mice. Therefore, we explored whether 9-month-APP/PS1 mice with amyloid plaque pathology had

any alterations in cardiac function and arterial stiffness, and whether short term treatment with glyburide might reduce arterial stiffness (Figure 9). Echocardiography indicated similar heart rate, cardiac output, E/e' ratio, ejection fraction, fractional shortening and LV posterior thickness in WT-placebo, APP/PS1-placebo and APP/PS1-glyburide treated mice (Figure 9B), demonstrating that APP/PS1 did not have an overt cardiac phenotype at 9 months of age. Moreover, short term glyburide treatment in the APP/PS1 mice had no adverse effect on cardiac function. In contrast, there was a trend towards higher pulse wave velocity in APP/PS1-placebo mice (8.7 ± 1.2 mm/ms; $n = 5$) compared to wild type-placebo mice (5.5 ± 1.0 mm/ms; $n = 7$), suggestive of increased arterial stiffness (Figure 10C). Interestingly, there was a trend towards decreased pulse wave velocity in glyburide-treated APP/PS1 mice (4.9 ± 1.1 mm/ms; $n = 5$), suggesting a normalization of this phenotype with glyburide treatment (Figure 10C). Higher pulse wave velocity is indicative of arterial stiffness and correlates with changes in cerebrovascular function [43-46]. This suggests the possibility that glyburide reversal of cerebrovascular dysfunction in APP/PS1 mice might underlie the cerebrovascular morphology changes observed with CD31/CD13 staining above.

We also investigated whether short-term glyburide treatment in older (8 mo.) APP/PS1 mice might affect learning and memory or brain network functional connectivity (fc) (Fig 11). On the Morris Water Maze behavioral test of learning and memory, glyburide treatment trended towards improvement compared to placebo (Fig 11A-C); both glyburide- and placebo-treated APP/PS1 mice demonstrated learning by decreasing the latency to platform over the 5-day testing period (Fig 11D), and both spent more time in the target quadrant than other quadrants (Fig 11B). Interestingly, glyburide-treated mice showed a trend towards increased platform crossings compared to placebo treated controls (Fig 11C), suggesting improved memory. Functional connectivity intrinsic signal imaging (fcOIS), to assess brain network function connectivity, revealed no differences between wildtype, placebo treated APP/PS1, and glyburide treated APP/PS1 mice at this time point (Fig 11D). This suggests that neither the disease nor therapy negatively affected network connectivity, and together with the above data, suggests that short term glyburide treatment can partially reverse functional deficits in APP/PS1 mice with established amyloid plaque pathology, without adverse effects.

DISCUSSION

Altered vascular K_{ATP} channel function in AD. K_{ATP} channels are present in neurons and in vascular cells and are important links between cell metabolism and excitability [12], but their role in AD pathology has largely been unexplored. Our initial finding that the vascular-expressed isoforms (*KCNJ8*, *ABCC9*), but not the neuronal (*KCNJ11*, *ABCC8*) are specifically upregulated in AD, provides a first indication that vascular K_{ATP} channels may be an important, targetable component of AD. Our studies show that peripheral administration of glyburide decreased amyloid burden and stimulus driven neural and hemodynamic activity, which ultimately reduced A β aggregation. Given that glyburide does not efficiently cross the BBB and that vascular K_{ATP} channels regulate vasoreactivity, we hypothesized that enhanced vascular K_{ATP} activity in AD- confirmed by transcriptomic data- might alter the structure and function of the cerebrovasculature. Glyburide-induced reversal of vascular remodeling and transcriptomic changes associated with vessel hypertrophy, as well as

arterial stiffness, suggest that K_{ATP} channels play a critical, previously unappreciated, and targetable role linking $A\beta$ with neurovascular dysfunction in AD (Fig 12).

Vascular K_{ATP} channels modulate the activity dependent release of $A\beta$ and amyloid plaque formation. In this study, reductions in $A\beta$ deposition and amyloid plaque load were due to changes in $A\beta$ production, not $A\beta$ clearance. One of the most potent drivers of $A\beta$ release is increased neuronal activity [2, 10, 37, 38, 47]. Previous studies demonstrate that the bidirectional modulation of neuronal activity correlates with $A\beta$ levels in the hippocampal ISF. Moreover, if neuronal activity is chronically increased or decreased, via stimulation, deprivation, [10, 37] or modification to sleep [4, 48, 49], amyloid plaque burden is altered in concert. Therefore, the formation of amyloid plaques is both activity- and concentration-dependent. In this study, we explored whether peripheral glyburide treatment decreased neuronal activity and $A\beta$ plaque load. Using electrical and pharmacological stimulation paired with EEG recordings, our work illustrates that the evoked response in the glyburide-treated group was diminished compared to placebo control when presented with the same stimulus. We further demonstrated that reductions in neuronal activity also decreased $A\beta$ production. This effect was surprising because studies in rodents [29], non-human primates [50], or humans [51] show that glyburide does not efficiently cross the blood brain barrier (BBB). In fact, administration of glyburide directly to the CNS prompts neuronal K_{ATP} channel closure and increases neuronal activity, leading to increased ISF $A\beta$ levels [7, 14]. This strongly argues that the paradoxical reduction in $A\beta$ production and aggregation by glyburide is not due to direct inhibition of neuronal K_{ATP} channels, but rather on vascular K_{ATP} channels. Previous work shows that vascular K_{ATP} channels play a major role in the cardiovascular system, where they regulate vasodilation, vasoconstriction, and vascular tone [12, 13, 52, 53]. Opening and closing of K_{ATP} channels triggers vasodilation and vasoconstriction, respectively, which is central to the neurovascular response and necessary to sustain periods of heightened neuronal activity. We demonstrate that the evoked hemodynamic response was dampened in the glyburide-treated APP/PS1 mice compared to placebo, explaining attenuated cerebral blood flow (CBF) and oxy-hemoglobin in the glyburide group when presented with the same stimulus as the placebo group. This suggests that glyburide affects the neurovascular unit in a manner that reduces the activity-dependent release of $A\beta$. Traditionally, neurovascular coupling (NVC) describes how changes in local neural activity drive changes in local cerebral blood flow [54]. Because neurons do not contain their own energy stores, they rely on the vasculature to provide energy substrates (e.g. oxygen and glucose) to meet local metabolic demand to sustained neuronal activity [55-57]. However, we hypothesize that glyburide acts through the less explored concept of vasculo-neural coupling (VNC) – where changes in vascular tone feed forward to alter neural activity and $A\beta$ release [58-61]. It is well established that K_{ATP} channel activation and inhibition contribute to vascular tone. Our data demonstrate that glyburide treatment reduces arterial stiffness and increases distensibility in a mouse model of $A\beta$ overexpression. Although it is unclear whether glyburide alters vasoreactivity both during a task and at rest, existing evidence supports the idea that changes in vascular K_{ATP} channel activity could restore vascular tone and feedforward to decrease the activity dependent release of $A\beta$ [62-65].

Implications for future AD treatment. This study is provocative for several reasons. First, it suggests that targeting the vasculature, in this case vascular K_{ATP} channels, holds therapeutic promise for AD. Traditional

dogma suggests that CNS therapeutics for AD must cross the BBB in order to be efficacious. In fact, one of the biggest hurdles for treating CNS diseases is effective BBB transport and targeted delivery of therapeutics to vulnerable brain regions. Our study adds to the growing body of evidence that a mechanistic approach to targeting vascular dysfunction holds therapeutic promise in AD.

Secondly, our study supports the evolving treatment strategies could be beneficial in AD despite alterations in CBF. It is well established in humans and rodent models that vascular dysfunction, including decreased CBF, is a pathological hallmark in AD [66-73]. It is also well established that evoked changes in CBF exceed local oxygen demand from increased neuronal activity [74] and changes in the blood oxygen level-dependent (BOLD) signal do not always reliably correlate with neuronal activity [75]. Thus, reducing stimulus-evoked hemodynamic activity does not necessarily equate to reduced neuronal activity or impaired cerebral metabolism. In fact, our data shows the opposite- oxygen consumption, oxygen extraction fraction, and cerebral metabolism are preserved (Fig 6). Since glyburide also reduced arterial stiffness, normalized pericyte-endothelial cell morphology, and improved memory, systemic glyburide treatment was beneficial to functional outcomes. Further studies are needed to fully understand the complex relationship between K_{ATP} channel activity, the neurovascular response, and Alzheimer's-related pathology.

Second, this study is provocative because it supports the idea that K_{ATP} channels are present in vascular cells in addition to neurons [12, 13] and both of which can be activated or inhibited to be beneficial in AD [76-78]. For example, diazoxide, a K_{ATP} channel agonist, hyperpolarizes multiple neuronal subtypes to reduce neuronal excitability and A β /tau release when delivered directly to neurons or the CNS [76]. However, when the K_{ATP} channel antagonists, glibenclamide [77] or tolbutamide [78], are administered orally, depression, anxiety, and memory deficits are reduced following the intracerebroventricular administration of A β oligomers [77]. Collectively, these studies demonstrate the following: 1) the route of drug administration dictates whether vascular or neuronal K_{ATP} channels are modulated and 2) inhibiting vascular K_{ATP} channels or activating neuronal K_{ATP} channels both reduce AD-related pathology and behavioral deficits by modulating aberrant cellular excitability. Together, this demonstrates an underappreciated role for K_{ATP} channel activity in the pathogenesis of Alzheimer's disease.

In our model, we hypothesize that increased A β production and aggregation causes vascular remodeling [68, 70], potentially as a consequence of increased vascular K_{ATP} activity, similar to what is seen in Cantu syndrome. Cantu syndrome arises from specific gain-of-function mutations in *KCNJ8* or *ABCC9* [17, 18, 53, 79] and is characterized by chronic vasodilation and decreased vascular tone. This leads to impaired vasoreactivity, and other cardiovascular abnormalities. Importantly, these cardiovascular perturbations can be reversed by glyburide treatment in rodents [17] and potentially in humans [80], consistent with what is observed in our preclinical study with AD-related pathology.

Taken together, we suggest that increased oligomeric A β results in K_{ATP} channel activation and vascular dilation, perhaps similar to Cantu syndrome. K_{ATP} channel inhibition with glyburide can reverse these defects, reducing the progression of A β related pathology in AD. Our studies demonstrate a critical and previously unappreciated role of K_{ATP} channels in linking neurovascular function and A β aggregation in Alzheimer's disease. Our data further suggest a direct, potential therapeutic approach – targeted inhibition of

vascular K_{ATP} channels - to delaying the onset and progression of cognitive impairment in those with underlying A β pathology.

METHODS

Gene expression alternations in AD brains. To determine whether K_{ATP} channel genes were differentially expressed in AD brain tissue, we analyzed gene expression of pleiotropic genes in publicly available datasets. We analyzed gene expression data from the Mayo Clinic Brain Bank (Mayo) RNAseq study from the Accelerating Medicines Partnership – Alzheimer's Disease (AMP-AD) portal: the temporal cortex of 80 control, 82 AD, 84 progressive supranuclear palsy (PSP), and 29 Pathologic Aging (PA) brains (syn3163039; syn5550404). Multi-variable linear regression analyses were performed using CQN normalized gene expression measures and including age at death, gender, RNA integrity number, brain tissue source, and flowcell as biological and technical covariates [81].

APPswe/PS1 Δ E9 mice. 4-month-old female mice hemizygous transgenic mice for mutations in amyloid precursor protein (APP) and presenilin 1 (PSEN1), the APPswe/PS1 Δ E9 mice (1) (APP/PS1) or wildtype littermates on a B6C3 background were used for studies described below. For pulse wave velocity, behavioral, and functional connectivity studies, mice were 9 months of age. Mice were given food and water ad libitum and maintained on a 12:12 light/dark cycle.

Drug pellet implantation. Glyburide or placebo pellets at a concentration of 2.5mg per 90-day release were purchased from Innovative Research of America (Sarasota, FL) and implanted subcutaneously as previously described [36]. Briefly, 4-month-old APP/PS1 mice were anesthetized with isoflurane, the skin on the lateral side of the neck lifted, and pellets implanted subcutaneously using a stainless steel precision trochar (Innovative Research of America, Sarasota, FL). Based on previous studies, continuous release pellet equates to 30 μ g/day (2.5mg/pellet; 30 μ g/day)[29, 36]. For pulse wave velocity, behavioral, and functional connectivity studies, mice were pelleted at 6.5 months and testing performed 2 month later at 8.5 months of age.

In vivo microdialysis. Guide cannulas (BR-style, Bioanalytical Systems) were stereotactically implanted into the hippocampus (from bregma, A/P: -3.1mm, M/L: -2.5mm, D/V: -1.2mm at 12° angle) and secured into place with dental cement. Cresyl violet staining was used to validate probe placement post-mortem. Mice were transferred to Ratan sampling cages (Bioanalytical Systems) and microdialysis probes (2 mm; 38 kDa molecular weight cut-off; BR-style, Bioanalytical Systems) inserted into the guide cannula, connected to a syringe pump and infused with artificial cerebrospinal fluid (aCSF; 1.3mM CaCl₂, 1.2mM MgSO₄, 3mM KCl, 0.4mM KH₂PO₄, 25mM NaHCO₃ and 122mM NaCl; pH=7.35) at a flow rate of 1 μ l/minute. Hourly collection of hippocampal ISF began after an 8 hour acclimation period. Steady state levels of ISF glucose, lactate, and A β 1-x were assayed as described below.

Drug administration via reverse microdialysis. To determine the clearance rate of ISF A β and its half-life in the ISF, Compound E (200 μ M; Enzo Life Sciences), a gamma secretase inhibitor, was infused directly into the hippocampus via reverse microdialysis as previously described (3). Hourly fractions of ISF were collected and A β 1-x was measured to calculate half-life as previously described. To determine the activity dependent release of A β , picrotoxin (PTX; 25 μ m) was administered via reverse microdialysis, hourly ISF fractions were

collected and A β 1-x measured as described below. Statistical significance was determined using a one-way ANOVA and Dunnett's multiple comparison post-hoc test. Data is represented by means $\pm$ SEM.

Tissue processing for post-mortem analyses. 7-month-old APP/PS1 mice were anesthetized with an overdose of sodium pentobarbital and transcardially perfused with heparinized ice-cold phosphate buffered saline (PBS). The brains were removed and dissected out. One hemisphere fixed in 4% paraformaldehyde for 48 hrs at 4°C, and cryoprotected in 30% sucrose for immunohistochemical procedures. Brains were sectioned on a freezing microtome at 50 μ m. Serial sections (300 μ m apart) through the anterior-posterior aspect of the hippocampus were used for immunostaining and quantification. Brain regions from the contralateral hemisphere, including the anterior cortex, posterior cortex, hippocampus, striatum, cerebellum, hypothalamus, and septum, were dissected out and flash frozen. Specific brain regions were further processed for ELISAs, western blot, and qPCR. For ELISAs, hippocampal tissue was hand homogenized in 10x w/v RIPA buffer with protease and phosphatase inhibitors (Roche). Homogenates were centrifuged at 14,000 rpm for 30 minutes at 4°C. Supernatant was collected and used as tissue lysate. Total protein concentration in lysates was determined by Micro BCA (ThermoScientific) according to manufacturer's instructions.

Immunohistochemical and quantification procedures for A β , X34, GFAP, CD68, Iba1, CD31, and CD13 staining. Serial sections (300 μ m apart) through the anterior-posterior aspect of the hippocampus were immunostained for either A β deposition or X-34. For A β deposition, free floating sections were stained using a biotinylated, HJ3.4 antibody (anti-A β 1–13, mouse monoclonal antibody generated in-house) and developed using a Vectastain ABC kit and DAB reaction. For fibrillary plaques, free floating sections were permeabilized with 0.25% Triton X-100 and stained with 10 μ M X-34 in 40% ethanol + 0.02M NaOH in PBS [82]. For GFAP, CD68, Iba1, CD13, and CD31x staining, free floating sections were blocked with 3% donkey serum and incubated overnight with either rabbit anti-GFAP (1:10000, Dako), rat anti-CD68 (1:200, BioRad), or rabbit anti-Iba1 (1:5000, Wako). Stained brain sections were imaged using a NanoZoomer slide scanner (Hamamatsu Photonics) and the percent area occupied by HJ3.4 or X-34 was quantified by a blinded researcher as previously described[7, 83]. Statistical significance was determined using a two-tailed, unpaired t-test. Data is represented by means $\pm$ SEM.

A β 1-x, A β 40, and A β 42 ELISA. For total A β concentrations within the hippocampal ISF, A β 1-x was quantified using a monoclonal capture antibody targeted against A β 13-28 (m266) and a biotinylated detection antibody targeted against A β 1-5 (3D6), both generous gifts from Dr. Ron DeMattos, Eli Lilly and Co., Indianapolis, IN. After incubation with streptavidin-poly-HRP-20, the assay was developed using Super Slow TMB (Sigma) and the plates read on a Bio-Tek Synergy 2 plate reader at 650nm. For A β 40 and A β 42 levels, the soluble and insoluble fractions of hippocampal tissue homogenates were isolated and assayed using sandwich ELISAs as previously described[7, 82]. Briefly, A β 40 & A β 42 were quantified using monoclonal capture antibodies targeted against amino acids 45-50 (HJ2) or 37-42 (HJ7.4), respectively. For detection, both A β 40 and A β 42 used a biotinylated monoclonal antibody against the central domain (HJ5.1B), followed by incubation with streptavidin-poly-HRP-40. Assays were developed using Super Slow TMB (Sigma) and the plates read on a Bio-Tek Synergy 2 plate reader at 650nm.

Glucose and lactate measurements. Glucose and lactate measurements from blood and hippocampal ISF were quantified using an YSI 2900 analyzer as previously described [7, 84].

Insulin ELISAs. Serum was collected after 5 hours of fasting and insulin was measured by ELISA (Alpco: Cat. # 80-INSMSU-E01; 80-CPTMS-E01) according to manufacturer's instructions[83].

Insulin degrading enzyme (IDE) activity assay. IDE activity was measure in cortical homogenates post-treatment for 1 hour using the SensoLyte IDE Activity Assay Kit (AnaSpec, Inc: Cat. # AS-72231) according to manufacturer's instructions. Frozen cortex was hand homogenized 5x w/v in assay buffer, centrifuged, and the supernatant used as lysate. Fluorescence was measured every 10 minutes for 90 minutes and the relative fluorescence at 90 minutes per mg of protein (determined by MicroBCA) was quantified.

qPCR analysis. RNA isolation from mouse brain was performed as previously described [85]. Briefly, anterior cortex was homogenized by trituration through a 23-gauge needle in TRIzol (Invitrogen). Chloroform (1:5) was added, samples mixed, then centrifuged at 13,000 g for 15 minutes at 4°C. Chloroform was removed, diluted 1:1 in 70% ethanol, and purified using RNeasy columns and reagents (QIAGEN). RNA concentration was measured using a NanoDrop spectrophotometer, and reverse transcription was performed using a high-capacity RNA-cDNA kit (Applied Biosystems [ABI]) with 1 µg RNA per 20 µl reaction. Real-time qPCR was performed with ABI TaqMan primers and reagents on an ABI Prizm 7500 thermocycler according to the manufacturer's instructions. All mRNA measurements were normalized to β-actin mRNA levels.

Western blot analyses for APP metabolism. Cortical tissue was homogenized in 10-fold volume lysis buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, and 150 mM NaCl) and centrifuged at 15,000 g at 4°C. 50 µg of protein were loaded following quantification with a BCA assay onto a 4–20% Bis-Tris gel and transferred to nitrocellulose membrane. Full-length APP was detected using 6E10 (1:1,000; Biolegend), and C99 fragment was detected using 82E1 (1:1,000; IBL America). Protein detection was visualized using an HRP-coupled anti-mouse secondary antibody (1:5,000) and ECL reagent. Images of the blot were captured using a G Box (SynGene) and analyzed in ImageJ[82].

Forepaw stimulation. Needle electrodes were inserted into the dorsal and ventral sides of the left and right forepaws between digits 2 and 3. The stimulation paradigm consisted of 5 seconds of rest, followed by a 10 second stimulus train, then 45 seconds of rest administered in a block design (15 trials per mouse). Electrical stimuli were 0.3ms pulses delivered at 3Hz at an amplitude of 1mA driven by a constant current stimulus isolation unit (World Precision Instruments).

Functional neuroimaging. Six weeks post glyburide or placebo pellet implantation, mice were imaged using interleaved optical intrinsic signal imaging (OISI) and laser speckle contrast imaging (LSCI) under Ketamine/Xylazine anesthesia (Ketamine: 86.9mg/kg; Xylazine: 13.4mg/kg) as previously described [86–88]. Temporal multiplexing of these modalities allows for simultaneous imaging of relative changes in oxygenated (HbO) deoxygenated (HbR), and total (HbT) hemoglobin, and cerebral blood flow (CBF). All mice were imaged in 2 separate sessions separated by 1 week: a stimulus session in which mice were imaged for 15 minutes during forepaw stimulation, and a resting state session during which mice were imaged for 45 min). All imaging data were acquired at 30 Hz. Data from all mice were subject to an initial quality check prior to analysis. Data runs in which reflected light level intensity (mean value over the brain) varied as a function of time by greater than 1%

for any wavelength were excluded from further analysis. Evoked hemodynamics were bandpass filtered from 0.009-0.5 Hz, and resting state activity was bandpass filtered from 0.009-0.08 Hz. After filtering, each pixel's time series was downsampled from 30 Hz to 1 Hz, and all further analysis was performed only on those pixels labeled as brain using a manually-constructed brain mask. Common variance across all brain pixels was removed using global signal regression [89]. Image sequences were coregistered to a common atlas space as previously described[90]. Changes in relative CMRO₂ were calculated from the image sequences of CBF, HbO and HbR, and assuming values for the vascular weighting constants and baseline concentrations of HbO and HbR following established protocols [87]. Oxygen extraction fraction (OEF) was estimated as $OEF = CMRO_2 / CBF$ (i.e. assuming 100% arterial oxygen saturation and 0% venous oxygen saturation). Time courses for each contrast were created by averaging all pixel time courses within 50% of peak response within forepaw somatosensory cortex.

Resting state functional connectivity. RSFC was performed as previously described [90]. Briefly, fourteen seed locations were positioned at coordinates corresponding to left and right frontal, cingulate, motor, somatosensory, retrosplenial, and visual cortices. Seed time traces were calculated by averaging time traces within 0.25 mm (30 pixels) of a seed locus and correlated with every other pixel in the brain to create a functional connectivity map for that seed. Individual functional connectivity maps were averaged within each cohort. Bilateral connectivity was determined by correlating each seed with its contralateral homolog, thus producing seven bilateral correlation values for each mouse. Pearson r values were converted to Fisher Z measures prior to any averaging or statistical comparison.

EEG recordings. Six weeks post glyburide or placebo pellet implantation, APP/PS1 mice were subjected to electroencephalography (EEG) recordings in S1FL region of cortex contralateral to forepaw stimulation as previously described[91]. Whiskers are stimulated for 10s on and 50 second off. EEG activity is assessed using a P511K A.C. preamplifier (Grass Technologies), digitized with a DigiData 1440A data acquisition system (Molecular Devices) and recorded digitally using pClamp 10.2 (Molecular Devices). Changes in EEG amplitude and power analysis during the whisker stimulation will be compared to baseline in each animal. Group averages in EEG amplitude during stimulation compared to baseline will be calculated for each group.

Plexiglass window implantation. Prior to imaging, Plexiglas windows were affixed to mouse skulls as previously described[92]. Briefly, mice were anesthetized with isoflurane (5% induction, 2% maintenance) with their heads secured in a stereotaxic frame, and placed on a heating pad maintained at 37°C (via feedback from a rectal probe). After shaving and cleaning the scalp, a midline incision was made along the scalp, keeping the skull intact. A clear Plexiglas window with pre-tapped holes was fixed with translucent dental cement (C&B-Metabond, Parkell Inc., Edgewood, NY), and a Plexiglas coverslip was screwed onto the imaging window to protect the window from scratching while the mice were in their home cages. Post-surgery, mice were returned to their home cages and allowed to recover for at least 72 hrs. The total mass of the window, screws, and cover was approximately 1 g.

Microarray analysis. Microarray was performed on the anterior cortex from 7 month-wildtype-placebo, APP/PS1-glyburide treated, and APP/PS1-placebo (n=4 mice/group) following transcardial perfusion as

previously described [93]. RNA was isolated from flash frozen cortex samples as above and submitted to the Genome Technology Access Center at Washington University for quality control, MessageAmp RNA library preparation with Kreatech ULS, and Agilent Mouse 8x60K microarray. Differentially expressed genes (DEGs) were identified using Bayesian statistics, where significant genes were filtered out with a p value < 0.05 or FDR- $q < 0.05$, and a fold-change ≥ 2 . For Ingenuity Pathway Analysis (QIAGEN, Venlo, Netherlands), fold changes and p -values were imported for all expression values. Networks and pathways were analyzed for significant enrichment of module genes and were ranked by $-\log p$ -values. To quantify a significant association between differentially expressed genes and molecular in annotated pathways, a right-tailed Fisher's exact test was employed [94]. P -values of < 0.05 , FDR < 0.003 was considered significant.

Pulse wave velocity and cardiac function. Cardiac function and arterial stiffness were assessed in 9-month-old female wildtype-Placebo, APP/PS1-Placebo and APP/PS1-Glyburide. The thoracic area was treated with hair removal cream before imaging. Transthoracic echocardiography was performed using a Vevo 2100 LAZR ultrasound system (FUJIFILM/VisualSonics, Inc.; Toronto, Canada) equipped with a 30 MHz linear array transducer [95]. Mice were lightly anesthetized (1-1.5% inhaled isoflurane) and animals were placed in temperature controlled platform with two-lead electrodes to monitor heart rate during imaging. Parasternal short-axis along with 2-D mode images were obtained to assess stroke volume, heart rate, cardiac output, posterior wall thickness, ejection fraction, and fractional shortening [96, 97]. Mitral valve early filling velocities (E) and septal annular velocities (e') were obtained using pulsed Doppler and tissue Doppler, respectively. E/e' was calculated as an index of left ventricular (LV) filling pressure [96, 98]. To determine arterial stiffness, the pulse wave velocity was calculated as follows: $PWV = \text{Distance (D)} / \text{Time (T)}$, where D is the distance in mm between the ascending aorta site to descending aorta site and $T = (\text{R point of the EKG to the foot of the ascending aorta flow}) - (\text{R point of the EKG to the foot of the descending aorta flow})$ in msec [98]. All images were acquired and analyzed with Fujifilm Visualsonic VevoLab software (Version 3.2.6).

Morris water maze. Morris water maze (MWM) was performed as previously described [99]. Briefly, the test consisted of four trials (60-second maximum, 15 minute interval) per day for five consecutive days. Escape latency was measured as an average of four trials each day. A probe trial was conducted two hours after the final training session of the fifth day. The visible platform task consisted of four trials each day for two days with the escape platform marked by a visible cue and moved randomly among 4 locations. Trajectories, time spent in each maze quadrant, velocity, and distance moved were recorded using ANY-Maze tracking software (Stoelting Co., Wood Dale, IL).

Statistics. Statistical analysis using t-tests, one-way ANOVAs, and 2way ANOVAs and the appropriate post-hoc tests were performed for each experiment above. P values equal to or less than 0.05 were considered significant.

Study Approval. All procedures were carried out in accordance with an approved IACUC protocol from Wake Forest School of Medicine or Washington University School of Medicine.

AUTHOR CONTRIBUTIONS

SLM and DMH conceived of the study. SLM, DMH, MSR, CGN, AQB, JPC, NCD, CMK, LAC, and DID contributed to study design. SLM, MSS, EEC, WRM, ARB, NCD, CMC, SMD, JG, TEM, JAS, TEO, AQB, LAC, DID, and CMK performed experiments, data analysis, and data interpretation. SLM, CGN, and DMH wrote the manuscript. All authors discussed the results and commented on the manuscript.

ACKNOWLEDGEMENTS

We would like to acknowledge the following grants: 1K01AG050719 (SLM), R01AG068330 (SLM), BrightFocus Foundation (A20201775S; SLM), Charleston Conference on Alzheimer's disease New Vision Award (SLM), R01NS102870 (AQB), the McDonnell Center for Systems Neuroscience (SLM and AQB), P01NS080675 (DH, AQB, SLM, JC), R01 HL140024 (CGN), F31AG066302 (CC), T32AG033534 (JG), and T32AA007565 (SD). We would also like to acknowledge the Mayo Clinic Brain Bank (Mayo) RNAseq study from the Accelerating Medicines Partnership – Alzheimer's Disease (AMP-AD) portal. Study data were provided by the following sources: The Mayo Clinic Alzheimers Disease Genetic Studies, led by Dr. Nilufer Taner and Dr. Steven G. Younkin, Mayo Clinic, Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimers Disease Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, NINDS grant R01 NS080820, CurePSP Foundation, and support from Mayo Foundation. Study data includes samples collected through the Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona. The Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinsons Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimers Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimers Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinsons Research.

CONFLICT OF INTEREST STATEMENT

SLM served as a consultant for Denali Therapeutics. DMH is as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. DMH co-founded and is on the scientific advisory board of C2N Diagnostics. C2N Diagnostics has licensed certain anti-tau antibodies to AbbVie

for therapeutic development. DMH receives research grants from C2N Diagnostics, NextCure, and Novartis. DMH is on the scientific advisory board of Denali and consults for Genentech, Merck, Eli Lilly, and Cajal Neurosciences.

Figure Legends

Figure 1. Increased vascular K_{ATP} channel expression in the temporal cortex of Alzheimer's disease patients at autopsy. (A) Workflow to explore how K_{ATP} channel genes (*ABCC8*, *ABCC9*, *KCNJ8*, *KCNJ11*) in the temporal cortex change due to AD-related pathology using the Mayo RNAseq database. (B&C) Increased K_{ATP} channel subunit expression in the cortex of Alzheimer's patients (AD), but not in normal controls (NC), pathological aging (PA), or progressive supranuclear palsy (PSP). Significant changes (q value < 0.05 ; bolded and italicized) were observed in *KCNJ8* (q value= $2.43E-07$) and *ABCC9* (q value= $1.76E-05$), but not in *KCNJ11* and *ABCC8*. *KCNJ8* and *ABCC9* heterodimerize to form K_{ATP} channels on the vasculature, including mural cells, pericytes, and endothelial cells.

Figure 2. Systemic treatment with the sulfonylurea, glyburide, reduces $A\beta$ and plaque pathology in APP/PS1 mice. (A) Representative images from the cortex and hippocampus of glyburide and placebo treated mice stained for $A\beta$ deposition (HJ3.4B) and plaque pathology (X34; $n=9-10$ mice/group). (B) $A\beta$ deposition decreased in glyburide treated mice compared to placebo in the cortex and hippocampus by 48% and 50%, respectively. (C) Plaque pathology decreased in glyburide treated mice compared to placebo in both the cortex and hippocampus by 47% and 43%, respectively. (D) The insoluble levels of $A\beta_{40}$ and $A\beta_{42}$ decreased by 42% and 30%, respectively, in hippocampus of glyburide treatment mice. Significance determined via t-test with $*p<0.05$; $**p<0.001$.

Figure 3. Systemic glyburide treatment does not affect $A\beta$ clearance mechanisms. (A) There was no difference in $A\beta$ half-life following treatment with a gamma secretase inhibitor, compound E, in glyburide treated mice compared to placebo suggesting $A\beta$ clearance is not affected by glyburide treatment ($n=4-5$ mice/group). (B) There was no difference in $A\beta$ degrading enzymes, insulin degrading enzyme (*Ide*) or neprilysin (*Nep*), at either the transcript or protein level ($n=9$ mice/group). (C) No change in the mRNA levels of clearance related proteins, such as *Apoe*, *Lrp1*, *Aqp4*, or *Rage* ($n=9$ mice/group). Significance determined via t-test with n.s.= not significant.

Figure 4. Neuroinflammation is unchanged in glyburide treated mice compared to controls despite reduced $A\beta$ deposition. (A) Astrocyte activation (GFAP staining) was comparable in the cortex and hippocampus of glyburide- and placebo-treated mice ($n=9-10$ mice/group). (B) Levels of CD68 were comparable in glyburide group compared to placebo. (C) Triple labeling of mouse cortex for amyloid plaques (X-34, blue), astrocytes (GFAP, green), and microglia (Iba1, red) in glyburide and placebo treated mice. (D) No difference in area fraction, total number, or average size of microglia or astrocytes. (E) No difference in number of plaque

associated microglia between placebo and glyburide treated mice (amyloid plaques=X34; blue, astrocytes=GFAP; green, and microglia=CD68; red). Significance determined via t-test with n.s.= not significant.

Figure 5. Reduced evoked responses and ISF A β levels in glyburide treatment mice. (A) Left forepaw stimulation was paired with EEG recordings in the contralateral somatosensory cortex (S1BL). (B) Representative EEG traces from S1FL cortex during 10 seconds of stimulation followed by 50 seconds of rest. (C) Basal EEGs are similar between placebo and glyburide groups (n=5 mice/group). (D) During forepaw stimulation, EEG amplitude increased by ~40% in placebo group, but only 10% in glyburide group. (E) Steady state levels of ISF A β are lower in glyburide group compared to placebo. (F) PTX treatment increased ISF A β levels in placebo but not in glyburide group, while ISF lactate, a marker of neuronal activity, increased in both (n=6/group). (G) No difference in seizure frequency between groups post-PTX but variance in glyburide group decreased (n=6 mice/group). (H) Decreased amyloidogenic processing of APP was seen in glyburide mice (n=4-5 mice/group). Significance determined via t-test, one-way ANOVA, or two-way ANOVA with Tukey's post hoc tests when appropriate. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001

Figure 6. Glyburide treatment decreased stimulus-evoked hemodynamic activity in the cortex without altering cerebral or peripheral metabolism in APP/PS1 mice. (A) Group-averaged evoked time courses of oxygenated (HbOxy), Deoxygenated (HbDeOxy) and total (HbT) hemoglobin, cerebral blood flow (CBF), cerebral metabolic rate of oxygen consumption (CMRO2), and oxygen extraction fraction (OEF) following forepaw stimulation (n=8-9 mice/group). (B) Significant differences were observed in the responses for CBF, HbOxy, and HbT, but CMRO2 was preserved due to increased OEF in glyburide mice. (C) Steady state levels of ISF glucose and lactate were similar in placebo and glyburide groups (n=4-6 mice/group). (D) Body weight, blood glucose levels, and serum insulin levels were comparable in placebo and glyburide groups (n=9-10 mice/group). Significance determined via t-test with *p<0.05; **p<0.001.

Figure 7. Glyburide restores pericyte-endothelial cell morphology. (A) High magnification image of CD31 (red; endothelial cells) and CD13 (green; pericytes) in wildtype, APP/PS1 placebo, and APP/PS1 glyburide groups (n=9-10/group). (B) Low magnification of CD31, CD13, and merged images from wildtype, APP/PS1 placebo, and APP/PS1 glyburide groups. (C) Quantification of CD31, CD13, vessel length, and vessel width in all groups. APP/PS1 placebo group has increased CD31 and CD13 staining as well as vessel width and vessel length in the cortex compared to wildtype mice. Glyburide treatment reduced all metrics to wildtype levels. Significance determined via one-way ANOVA with Tukey's posthoc tests with *p<0.05; **p<0.001. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Figure 8. Glyburide treatment reverses disease dependent changes gene expression in the cortex of mice and humans. (A) Venn diagram representing differential gene expression in the cortex of 1) APP/PS1 mice compared to WT controls and 2) glyburide treated APP/PS1 mice compared to placebo treated APP/PS1

control (n=4 mice/group). (B) Heat map highlighting the 32 differentially expressed genes altered due to disease (e.g. APP/PS1 placebo v WT placebo) and subsequently reversed by treatment (e.g. APP/PS1 glyburide v APP/PS1 placebo). (C) Of the genes differentially expressed in mice due to disease and normalized with treatment, a subset of these genes are also altered in the human brain from AD patients. These genes are involved in G-protein coupled receptor activity, signal transduction, redox reactions, neuroinflammation, and proteolysis.

Figure 9. Ingenuity pathway analysis (IPA) identified canonical pathways regulated by APP/PS1 genotype and responsive to glyburide treatment. (A) Venn diagram representing pathways affected by 1) APP/PS1 genotype compared to WT controls, 2) glyburide treatment compared to placebo treatment in APP/PS1 mice, and 3) glyburide treated APP/PS1 mice compared WT controls. APP/PS1 genotype upregulated 53 pathways while glyburide treatment downregulated 18 pathways. Treatment with glyburide restored 3 pathways to wildtype levels. (B) Type II Diabetes Mellitus Signaling, $G\alpha_q$ Signaling, and Cardiac Hypertrophy Signaling Pathways were upregulated due to APP/PS1 genotype (red), downregulated due to glyburide treatment (blue), and indistinguishable from WT (gray). (C) Genes differentially expressed in Type II Diabetes Mellitus, $G\alpha_q$, and Cardiac Hypertrophy Signaling Pathways upregulated in APP/PS1 mice and subsequently reduced in glyburide treatment compared to placebo. (D) Of the genes identified in Fig 9c in mice, a subset of these genes is also altered in the human brain from AD patients. These genes are largely involved in calcium signaling and G-protein coupled signal transduction suggesting glyburide alters excitability within the brain.

Figure 10. Cardiac function and arterial stiffness in wildtype and APP/PS1 mice following glyburide treatment. (A) Sample image of parasternal short-axis along with 2-D mode images used to assess cardiac function and pulse wave velocity. (B) Cardiac function was comparable between wildtype-placebo, APP/PS1-placebo and APP/PS1-glyburide treated mice on all metrics assessed (n=5-7 mice/group). (C) Pulse wave velocity, a metric of arterial stiffness, was assessed in wildtype-placebo, APP/PS1-placebo and APP/PS1-glyburide treated mice. APP/PS1 mice had a trend towards increased arterial stiffness compared to wildtype. Short term treatment with glyburide decreased pulse wave velocity and reduced arterial stiffness in APP/PS1 mice. Significance determined by one-way ANOVA with Tukey's test. p values reported to demonstrate trends.

Figure 11. Glyburide treatment improved learning and memory in APP/PS1 mice. (A) Both placebo and glyburide groups demonstrated the ability to learn on the Morris Water Maze (MWM) test by decreasing latency to platform over consecutive testing days ($p < 0.0001$; n=8 mice/group). (B) Both placebo and glyburide groups spent more time in target quadrant during probe trial ($p < 0.004$). (C) Glyburide treated APP/PS1 mice had increased platform crossings ($p < 0.06$) compared to placebo treated controls, suggesting improved learning and memory. (D) No change in functional connectivity was found in the cingulate (Cing), motor (Motor), somatosensory (SS), retrosplenial (RS), and visual (Vis) cortices either due to disease or treatment (n=5-7 mice/group). Significance determined by two-way ANOVA with Tukey's test. p values reported to demonstrate trends.

Figure 12. K_{ATP} channel inhibition with systemic glyburide reduces $A\beta$ pathology and vascular damage. Increased $A\beta$ oligomers and amyloid plaques contribute to vascular damage in AD. This coincides with increased expression of vascular K_{ATP} channels in the AD brain, which are important modulators of vasoreactivity. We demonstrate that peripheral treatment with the sulfonylurea and K_{ATP} channel inhibitor, glyburide, reduced the aggregation and activity-dependent production of $A\beta$. Our data suggest that glyburide targets vascular K_{ATP} channel activity to reduce arterial stiffness, improve vasoreactivity, and normalize pericyte-endothelial cell morphology, providing evidence that vascular K_{ATP} channels are an important, targetable component of Alzheimer's related pathology.

References

1. Cirrito, J.R., et al., *Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo*. Neuron, 2008. **58**(1): p. 42-51.
2. Cirrito, J.R., et al., *Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo*. Neuron, 2005. **48**(6): p. 913-22.
3. Holth, J.K., et al., *The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans*. Science, 2019.
4. Kang, J.E., et al., *Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle*. Science, 2009. **326**(5955): p. 1005-7.
5. Verges, D.K., et al., *Opposing synaptic regulation of amyloid-beta metabolism by NMDA receptors in vivo*. J Neurosci, 2011. **31**(31): p. 11328-37.
6. Yamada, K., et al., *Neuronal activity regulates extracellular tau in vivo*. J Exp Med, 2014. **211**(3): p. 387-93.
7. Macauley, S.L., et al., *Hyperglycemia modulates extracellular amyloid-beta concentrations and neuronal activity in vivo*. J Clin Invest, 2015. **125**(6): p. 2463-7.
8. Citron, M., et al., *Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production*. Nature, 1992. **360**(6405): p. 672-4.
9. Selkoe, D.J., *Alzheimer's disease: genes, proteins, and therapy*. Physiol Rev, 2001. **81**(2): p. 741-66.
10. Bero, A.W., et al., *Neuronal activity regulates the regional vulnerability to amyloid-beta deposition*. Nat Neurosci, 2011. **14**(6): p. 750-6.
11. Wu, J., et al., *Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent beta-amyloid generation*. Cell, 2011. **147**(3): p. 615-28.
12. Nichols, C.G., *KATP channels as molecular sensors of cellular metabolism*. Nature, 2006. **440**(7083): p. 470-6.
13. Foster, M.N. and W.A. Coetzee, *KATP Channels in the Cardiovascular System*. Physiol Rev, 2016. **96**(1): p. 177-252.
14. Huang, C.W., et al., *Glucose and hippocampal neuronal excitability: role of ATP-sensitive potassium channels*. J Neurosci Res, 2007. **85**(7): p. 1468-77.
15. Tanner, G.R., et al., *Single K ATP channel opening in response to action potential firing in mouse dentate granule neurons*. J Neurosci, 2011. **31**(23): p. 8689-96.

16. Nelson, P.T., et al., *ABCC9/SUR2 in the brain: Implications for hippocampal sclerosis of aging and a potential therapeutic target*. Ageing Res Rev, 2015. **24**(Pt B): p. 111-25.
17. McClenaghan, C., et al., *Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity*. J Clin Invest, 2020. **130**(3): p. 1116-1121.
18. Nichols, C.G., G.K. Singh, and D.K. Grange, *KATP channels and cardiovascular disease: suddenly a syndrome*. Circ Res, 2013. **112**(7): p. 1059-72.
19. Sola, D., et al., *Sulfonylureas and their use in clinical practice*. Arch Med Sci, 2015. **11**(4): p. 840-8.
20. Huang, C.C., et al., *Diabetes mellitus and the risk of Alzheimer's disease: a nationwide population-based study*. PLoS One, 2014. **9**(1): p. e87095.
21. Hsu, C.C., et al., *Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin*. J Alzheimers Dis, 2011. **24**(3): p. 485-93.
22. Gradman, T.J., et al., *Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes mellitus*. J Am Geriatr Soc, 1993. **41**(12): p. 1305-12.
23. Rubaiy, H.N., *The therapeutic agents that target ATP-sensitive potassium channels*. Acta Pharm, 2016. **66**(1): p. 23-34.
24. Caffes, N., et al., *Glibenclamide for the treatment of ischemic and hemorrhagic stroke*. Int J Mol Sci, 2015. **16**(3): p. 4973-84.
25. Gerzanich, V., et al., *Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitis*. J Neuroinflammation, 2017. **14**(1): p. 177.
26. Kurland, D.B., et al., *Glibenclamide for the treatment of acute CNS injury*. Pharmaceuticals (Basel), 2013. **6**(10): p. 1287-303.
27. Simard, J.M., et al., *Glibenclamide in cerebral ischemia and stroke*. Neurocrit Care, 2014. **20**(2): p. 319-33.
28. Jankowsky, J.L., et al., *Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase*. Hum Mol Genet, 2004. **13**(2): p. 159-70.
29. Lahmann, C., H.B. Kramer, and F.M. Ashcroft, *Systemic Administration of Glibenclamide Fails to Achieve Therapeutic Levels in the Brain and Cerebrospinal Fluid of Rodents*. PLoS One, 2015. **10**(7): p. e0134476.
30. Aziz, Q., Y. Li, and A. Tinker, *ATP-sensitive potassium channels and vascular function*. Channels (Austin), 2015. **9**(1): p. 3-4.
31. Chasseigneaux, S., et al., *Isolation and differential transcriptome of vascular smooth muscle cells and mid-capillary pericytes from the rat brain*. Sci Rep, 2018. **8**(1): p. 12272.

32. Daneman, R., et al., *The mouse blood-brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells*. PLoS One, 2010. **5**(10): p. e13741.
33. Aziz, Q., et al., *Molecular and functional characterization of the endothelial ATP-sensitive potassium channel*. J Biol Chem, 2017. **292**(43): p. 17587-17597.
34. Dunn-Meynell, A.A., N.E. Rawson, and B.E. Levin, *Distribution and phenotype of neurons containing the ATP-sensitive K⁺ channel in rat brain*. Brain Res, 1998. **814**(1-2): p. 41-54.
35. Griffith, C.M., et al., *Aberrant expression of the pore-forming KATP channel subunit Kir6.2 in hippocampal reactive astrocytes in the 3xTg-AD mouse model and human Alzheimer's disease*. Neuroscience, 2016. **336**: p. 81-101.
36. Remedi, M.S. and C.G. Nichols, *Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells*. PLoS Med, 2008. **5**(10): p. e206.
37. Yamamoto, K., et al., *Chronic optogenetic activation augments abeta pathology in a mouse model of Alzheimer disease*. Cell Rep, 2015. **11**(6): p. 859-865.
38. Cirrito, J.R., et al., *In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life*. J Neurosci, 2003. **23**(26): p. 8844-53.
39. Moshkforoush, A., et al., *The capillary Kir channel as sensor and amplifier of neuronal signals: Modeling insights on K(+)-mediated neurovascular communication*. Proc Natl Acad Sci U S A, 2020. **117**(28): p. 16626-16637.
40. Harraz, O.F., et al., *PIP2 depletion promotes TRPV4 channel activity in mouse brain capillary endothelial cells*. Elife, 2018. **7**.
41. Harraz, O.F., et al., *Endothelial GqPCR activity controls capillary electrical signaling and brain blood flow through PIP2 depletion*. Proc Natl Acad Sci U S A, 2018. **115**(15): p. E3569-E3577.
42. Harraz, O.F., D. Hill-Eubanks, and M.T. Nelson, *PIP2: A critical regulator of vascular ion channels hiding in plain sight*. Proc Natl Acad Sci U S A, 2020. **117**(34): p. 20378-20389.
43. Jefferson, A.L., et al., *Higher Aortic Stiffness Is Related to Lower Cerebral Blood Flow and Preserved Cerebrovascular Reactivity in Older Adults*. Circulation, 2018. **138**(18): p. 1951-1962.
44. Hughes, T.M., et al., *Arterial stiffness and beta-amyloid progression in nondemented elderly adults*. JAMA Neurol, 2014. **71**(5): p. 562-8.
45. Hughes, T.M., et al., *Pulse wave velocity is associated with beta-amyloid deposition in the brains of very elderly adults*. Neurology, 2013. **81**(19): p. 1711-8.
46. Hughes, T.M., S. Craft, and O.L. Lopez, *Review of 'the potential role of arterial stiffness in the pathogenesis of Alzheimer's disease'*. Neurodegener Dis Manag, 2015. **5**(2): p. 121-35.
47. Yan, P., et al., *Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice*. J Neurosci, 2009. **29**(34): p. 10706-14.

48. Holth, J.K., et al., *The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans*. Science, 2019. **363**(6429): p. 880-884.
49. Roh, J.H., et al., *Disruption of the sleep-wake cycle and diurnal fluctuation of beta-amyloid in mice with Alzheimer's disease pathology*. Sci Transl Med, 2012. **4**(150): p. 150ra122.
50. Tournier, N., et al., *Effects of selected OATP and/or ABC transporter inhibitors on the brain and whole-body distribution of glyburide*. AAPS J, 2013. **15**(4): p. 1082-90.
51. Marie, S., et al., *(11)C-glyburide PET imaging unveils the negligible brain penetration of glyburide in humans*. Neurology, 2019. **92**(17): p. 813-814.
52. Li, A., et al., *Hypotension due to Kir6.1 gain-of-function in vascular smooth muscle*. J Am Heart Assoc, 2013. **2**(4): p. e000365.
53. Huang, Y., et al., *Cardiovascular consequences of KATP overactivity in Cantu syndrome*. JCI Insight, 2018. **3**(15).
54. Iadecola, C., *The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease*. Neuron, 2017. **96**(1): p. 17-42.
55. Cauli, B., et al., *Cortical GABA interneurons in neurovascular coupling: relays for subcortical vasoactive pathways*. J Neurosci, 2004. **24**(41): p. 8940-9.
56. Lecrux, C. and E. Hamel, *Neuronal networks and mediators of cortical neurovascular coupling responses in normal and altered brain states*. Philos Trans R Soc Lond B Biol Sci, 2016. **371**(1705).
57. Lecrux, C., et al., *Pyramidal neurons are "neurogenic hubs" in the neurovascular coupling response to whisker stimulation*. J Neurosci, 2011. **31**(27): p. 9836-47.
58. Paton, J.F., et al., *Vascular-brain signaling in hypertension: role of angiotensin II and nitric oxide*. Curr Hypertens Rep, 2007. **9**(3): p. 242-7.
59. Moore, C.I. and R. Cao, *The hemo-neural hypothesis: on the role of blood flow in information processing*. J Neurophysiol, 2008. **99**(5): p. 2035-47.
60. Presa, J.L., et al., *Vasculo-Neuronal Coupling and Neurovascular Coupling at the Neurovascular Unit: Impact of Hypertension*. Front Physiol, 2020. **11**: p. 584135.
61. Thesen, T., et al., *Depression of cortical activity in humans by mild hypercapnia*. Hum Brain Mapp, 2012. **33**(3): p. 715-26.
62. Gozalov, A., et al., *Role of KATP channels in the regulation of rat dura and pia artery diameter*. Cephalalgia, 2005. **25**(4): p. 249-60.
63. Bayerle-Eder, M., et al., *Hypercapnia-induced cerebral and ocular vasodilation is not altered by glibenclamide in humans*. Am J Physiol Regul Integr Comp Physiol, 2000. **278**(6): p. R1667-73.
64. Esaki, T., et al., *Blockade of K(ATP) channels with glibenclamide does not alter functional activation of cerebral blood flow in the unanesthetized rat*. Brain Res, 2002. **948**(1-2): p. 56-63.

65. Nguyen, T.S., H.R. Winn, and D. Janigro, *ATP-sensitive potassium channels may participate in the coupling of neuronal activity and cerebrovascular tone*. Am J Physiol Heart Circ Physiol, 2000. **278**(3): p. H878-85.
66. Sweeney, M.D., S. Ayyadurai, and B.V. Zlokovic, *Pericytes of the neurovascular unit: key functions and signaling pathways*. Nat Neurosci, 2016. **19**(6): p. 771-83.
67. Montagne, A., et al., *Blood-brain barrier breakdown in the aging human hippocampus*. Neuron, 2015. **85**(2): p. 296-302.
68. Hall, C.N., et al., *Capillary pericytes regulate cerebral blood flow in health and disease*. Nature, 2014. **508**(7494): p. 55-60.
69. Mishra, A., et al., *Imaging pericytes and capillary diameter in brain slices and isolated retinæ*. Nat Protoc, 2014. **9**(2): p. 323-36.
70. Nortley, R., et al., *Amyloid beta oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes*. Science, 2019. **365**(6450).
71. Bell, R.D., et al., *Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging*. Neuron, 2010. **68**(3): p. 409-27.
72. Kisler, K., et al., *Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain*. Nat Neurosci, 2017. **20**(3): p. 406-416.
73. Iturria-Medina, Y., et al., *Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis*. Nat Commun, 2016. **7**: p. 11934.
74. Raichle, M.E. and M.A. Mintun, *Brain work and brain imaging*. Annu Rev Neurosci, 2006. **29**: p. 449-76.
75. Shaw, K., et al., *Neurovascular coupling and oxygenation are decreased in hippocampus compared to neocortex because of microvascular differences*. Nat Commun, 2021. **12**(1): p. 3190.
76. Liu, D., et al., *The KATP channel activator diazoxide ameliorates amyloid-beta and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease*. J Alzheimers Dis, 2010. **22**(2): p. 443-57.
77. Esmaeili, M.H., B. Bahari, and A.A. Salari, *ATP-sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity, depression- and anxiety-related symptoms in a rat model of Alzheimer's disease*. Brain Res Bull, 2018. **137**: p. 265-276.
78. Salgado-Puga, K., et al., *Subclinical Doses of ATP-Sensitive Potassium Channel Modulators Prevent Alterations in Memory and Synaptic Plasticity Induced by Amyloid-beta*. J Alzheimers Dis, 2017. **57**(1): p. 205-226.
79. Grange, D.K., et al., *Cantu syndrome: Findings from 74 patients in the International Cantu Syndrome Registry*. Am J Med Genet C Semin Med Genet, 2019. **181**(4): p. 658-681.
80. Ma, A., et al., *Glibenclamide treatment in a Cantu syndrome patient with a pathogenic ABCC9 gain-of-function variant: Initial experience*. Am J Med Genet A, 2019. **179**(8): p. 1585-1590.

81. Allen, M., et al., *Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases*. Sci Data, 2016. **3**: p. 160089.
82. Ulrich, J.D., et al., *ApoE facilitates the microglial response to amyloid plaque pathology*. J Exp Med, 2018. **215**(4): p. 1047-1058.
83. Stanley, M., et al., *The effects of peripheral and central high insulin on brain insulin signaling and amyloid- β in young and old APP/PS1 mice*. Journal of Neuroscience, 2016.
84. Kavanagh, K., et al., *Type-2-Diabetes Alters CSF but Not Plasma Metabolomic and AD Risk Profiles in Vervet Monkeys*. Front Neurosci, 2019. **13**: p. 843.
85. Musiek, E.S., et al., *Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration*. J Clin Invest, 2013. **123**(12): p. 5389-400.
86. Bergonzi, K.M., et al., *Mapping functional connectivity using cerebral blood flow in the mouse brain*. J Cereb Blood Flow Metab, 2015. **35**(3): p. 367-70.
87. Lee, J., et al., *Opposed hemodynamic responses following increased excitation and parvalbumin-based inhibition*. Journal of Cerebral Blood Flow & Metabolism, 2020: p. 0271678X20930831.
88. Lee, J., et al., *Opposed hemodynamic responses following increased excitation and parvalbumin-based inhibition*. Journal of Cerebral Blood Flow & Metabolism. **0**(0): p. 0271678X20930831.
89. White, B.R., et al., *Imaging of functional connectivity in the mouse brain*. PLoS One, 2011. **6**(1): p. e16322.
90. Bero, A.W., et al., *Bidirectional relationship between functional connectivity and amyloid-beta deposition in mouse brain*. J Neurosci, 2012. **32**(13): p. 4334-40.
91. Bauer, A.Q., et al., *Optical imaging of disrupted functional connectivity following ischemic stroke in mice*. Neuroimage, 2014. **99**: p. 388-401.
92. Bauer, A.Q., et al., *Effective Connectivity Measured Using Optogenetically Evoked Hemodynamic Signals Exhibits Topography Distinct from Resting State Functional Connectivity in the Mouse*. Cerebral Cortex, 2017. **28**(1): p. 370-386.
93. Lananna, B.V., et al., *Cell-Autonomous Regulation of Astrocyte Activation by the Circadian Clock Protein BMAL1*. Cell Rep, 2018. **25**(1): p. 1-9 e5.
94. Spradling, K.D., et al., *The baboon kidney transcriptome: analysis of transcript sequence, splice variants, and abundance*. PLoS One, 2013. **8**(4): p. e57563.
95. Smith, L.M., et al., *SIRT1 Mediates Septic Cardiomyopathy in a Murine Model of Polymicrobial Sepsis*. Shock, 2020. **54**(1): p. 96-101.
96. Ferrario, C.M., et al., *Cardiac angiotensin-(1-12) expression and systemic hypertension in rats expressing the human angiotensinogen gene*. Am J Physiol Heart Circ Physiol, 2016. **310**(8): p. H995-1002.

97. Cruz, N., et al., *Chronic administration of carvedilol improves cardiac function in 6-month-old Syrian cardiomyopathic hamsters*. Pharmacology, 2007. **80**(2-3): p. 144-50.
98. Lee, L., et al., *Aortic and Cardiac Structure and Function Using High-Resolution Echocardiography and Optical Coherence Tomography in a Mouse Model of Marfan Syndrome*. PLoS One, 2016. **11**(11): p. e0164778.
99. Beckelman, B.C., et al., *Genetic reduction of eEF2 kinase alleviates pathophysiology in Alzheimer's disease model mice*. J Clin Invest, 2019. **129**(2): p. 820-833.

Figure 1. Increased vascular K_{ATP} channel expression in the temporal cortex of Alzheimer's disease patients at autopsy. (A) Workflow to explore how K_{ATP} channel genes (*ABCC8*, *ABCC9*, *KCNJ8*, *KCNJ11*) in the temporal cortex change due to AD-related pathology using the Mayo RNAseq database. (B&C) Increased K_{ATP} channel subunit expression in the cortex of Alzheimer's patients (AD), but not in normal controls (NC), pathological aging (PA), or progressive supranuclear palsy (PSP). Significant changes (q value < 0.05; bolded and italicized) were observed in *KCNJ8* (q value=2.43E-07) and *ABCC9* (q value=1.76E-05), but not in *KCNJ11* and *ABCC8*. *KCNJ8* and *ABCC9* heterodimerize to form K_{ATP} channels on the vasculature, including mural cells, pericytes, and endothelial cells.

Figure 2. Systemic treatment with the sulfonylurea, glyburide, reduces A β and plaque pathology in APPswe/PSEN1dE9 mice. (A) Representative images from the cortex and hippocampus of glyburide and placebo treated mice stained for A β deposition (HJ3.4B) and plaque pathology (X34; n=9-10 mice/group). (B) A β deposition is decreased in glyburide treated mice compared to placebo in the cortex and hippocampus by 48% and 50%, respectively. (C) Plaque pathology is decreased in glyburide treated mice compared to placebo in both the cortex and hippocampus by 47% and 43%, respectively. (D) The insoluble levels of A β 40 and A β 42 were decreased by 42% and 30%, respectively, in hippocampus of glyburide treatment mice. Significance determined via t-test with *p<0.05; **p<0.001.

Figure 3. Systemic glyburide treatment does not affect A β clearance mechanisms. (A) There was no difference in A β half life following treatment with a gamma secretase inhibitor, compound E, in glyburide treated mice compared to placebo suggesting A β clearance is not affected by glyburide treatment (n=4-5 mice/group). (B) There was no difference in A β degrading enzymes, insulin degrading enzyme (*Ide*) or neprilysin (*Nep*), at either the transcript or protein level (n=9 mice/group). (C) No change in the mRNA levels of clearance related proteins, such as *Apoe*, *Lrp1*, *Aqp4*, or *Rage* (n=9 mice/group). Significance determined via t-test with n.s.= not significant.

Figure 4. Neuroinflammation is unchanged in glyburide treated mice compared to placebo controls despite reduced A β deposition. (A) Astrocyte activation (GFAP staining) was comparable in the cortex and hippocampus of glyburide- and placebo-treated mice ($n=9-10$ mice/group). (B) Levels of CD68 were comparable in glyburide group compared to placebo. (C) Triple labeling of mouse cortex for amyloid plaques (X-34, blue), astrocytes (GFAP, green), and microglia (Iba1, red) in glyburide and placebo treated mice. (D) No difference in area fraction, total number, or average size of microglia. (E) No difference in number of plaque associated astrocytes between placebo and glyburide treated mice (amyloid plaques=X34; blue, astrocytes=GFAP; green, and microglia=CD68; red). Significance determined via t-test with n.s.= not significant.

Figure 5. Reduced evoked responses and ISF A β levels in glyburide treatment mice. (A) Left forepaw stimulation was paired with EEG recordings in the contralateral somatosensory cortex (S1BL). (B) Representative EEG traces from S1FL cortex during 10 seconds of stimulation followed by 50 seconds of rest. (C) Basal EEGs similar in placebo and glyburide (n=5 mice/group). (D) During forepaw stimulation, EEG amplitude increased by ~40% in placebo, but only 10% in glyburide. (E) Steady state levels of ISF A β are lower in glyburide group. (F) PTX treatment increased ISF A β in placebo but not in glyburide group, while ISF lactate, a marker of neuronal activity, increased in both (n=6/group). (G) No difference in seizure frequency between groups post-PTX but variance in glyburide group was decreased (n=6 mice/group). (H) Decreased amyloidogenic processing of APP was seen in glyburide mice (n=4-5 mice/group). Significance determined via t-test, one-way ANOVA, or two-way ANOVA with Tukey's post hoc tests when appropriate. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001

A **B** **C** **D**

Figure 6. Glyburide treatment decreased stimulus-evoked hemodynamic activity in the cortex without altering cerebral or peripheral metabolism in APP/PS1 mice. (A) Group-averaged evoked time courses of oxygenated (HbOxy), Deoxygenated (HbDeOxy) and total (HbT) hemoglobin, cerebral blood flow (CBF), cerebral metabolic rate of oxygen consumption (CMRO₂), and oxygen extraction fraction (OEF) following forepaw stimulation (n=8-9 mice/group). (B) Significant differences were observed in the responses for CBF, HbOxy, and HbT, but CMRO₂ was preserved due to increased OEF in glyburide mice. (C) Steady state levels of ISF glucose and lactate were similar in placebo and glyburide groups (n=4-6 mice/group). (D) Body weight, blood glucose levels, and serum insulin levels were comparable in placebo and glyburide groups (n=9-10 mice/group). Significance determined via t-test with *p<0.05; **p<0.001.

A **Wildtype****APP/PS1 - placebo****APP/PS1 - glyburide** **B****Wildtype****APP/PS1
placebo****APP/PS1
glyburide** **C**

Figure 7. Glyburide restores pericyte-endothelial cell morphology. (A) High magnification image of CD31 (red; endothelial cells) and CD13 (green; pericytes) in wildtype, APP/PS1 placebo, and APP/PS1 glyburide groups (n=9-10/group). (B) Low magnification of CD31, CD13, and merged images from wildtype, APP/PS1 placebo, and APP/PS1 glyburide groups. (C) Quantification of CD31, CD13, vessel length, and vessel width in all groups. APP/PS1 placebo group has greater CD31 and CD13 staining as well as vessel width and vessel length in the cortex compared to wildtype mice. Glyburide treatment reduced all metrics to wildtype levels. Significance determined via one-way ANOVA with Tukey's posthoc tests with *p<0.05; **p<0.001. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

A **B** **C** **D**

Gene	Beta	pValue	Function
FFAR4	-1.175	2.29E-08	regulator of G protein-coupled receptor activity
DNMT3A	0.287	8.86E-04	regulator of DNA methylation and gene expression
ECT2L	-0.318	6.67E-03	guanyl-nucleotide exchange factor for signal transduction
IYD	-0.587	1.46E-02	regulator of oxidoreductase activity in redox reactions
METAP1D	-0.138	2.34E-02	regulator of metalloaminopeptidase activity and proteolysis
ADAM18	-0.360	4.91E-02	regulator of metallopeptidase activity and proteolysis

Figure 8. Glyburide treatment reverses disease dependent changes gene expression in the cortex of mice and humans. (A) Overview of workflow for gene expression experiments. (B) Venn diagram representing differential gene expression (DEGs) in the cortex of 1) APP/PS1 mice compared to wildtype controls and 2) glyburide treated APP/PS1 mice compared to placebo treated APP/PS1 mice (n=4 mice/group). (C) Heat map highlighting the DEGs altered by disease (e.g. APP/PS1 placebo v WT placebo) and reversed by treatment (e.g. APP/PS1 glyburide v APP/PS1 placebo). (D) Of the mouse DEGs, a subset were also altered in the human brain from AD patients. These genes are involved in G-protein coupled receptor activity, signal transduction, redox reactions, neuroinflammation, and proteolysis.

A

Comparison	Downregulated Pathways	Upregulated Pathways	Total Affected Pathways
APP/PS1 plac vs. WT plac	1	53	54
APP/PS1 glyb vs. APP/PS1 plac	18	0	18
APP/PS1 glyb vs. WT plac	3	43	46

B

APP/PS1 placebo v Wildtype placebo

APP/PS1 glyburide v APP/PS1 placebo

APP/PS1 glyburide v Wildtype placebo

C

Cardiac Hypertrophy

Type II Diabetes Mellitus Signaling

Gαq Signaling

D

Gene	Beta	pValue	Function
<i>MAP3K5</i>	0.540	2.76E-06	enables protein kinase activity and protein phosphorylation
<i>SOC3</i>	1.537	1.42E-04	negative regulator of signal transduction and apoptosis
<i>TNFRSF11B</i>	1.579	6.80E-08	involved in signal transduction and apoptosis
<i>PRKCH</i>	0.735	9.69E-06	enables protein kinase activity and protein phosphorylation
<i>NGFR</i>	0.585	4.65E-02	involved in calmodulin binding, Rho protein signal transduction, and apoptosis
<i>ARHGEF25</i>	-0.326	5.61E-03	enables guanyl-nucleotide exchange factor and Rho protein signal transduction
<i>AVPR1B</i>	-0.807	1.16E-03	regulator of G protein-coupled and vasopressin receptor activity
<i>GNB4</i>	0.791	1.78E-06	involved in signal transduction
<i>GNG7</i>	0.138	1.35E-02	involved in G protein-coupled receptor signaling pathway
<i>FZD10</i>	0.475	1.47E-02	involved in G protein-coupled receptor activity and Wnt signaling
<i>HSPB7</i>	0.489	1.19E-02	part of the actin cytoskeleton and cardiac development
<i>IGF1</i>	-1.095	1.13E-05	enables growth factor activity and signal transduction
<i>IL13RA1</i>	0.707	4.67E-05	involved in cytokine-mediated signaling
<i>PDE8B</i>	-0.232	8.56E-03	involved in 3',5'-cyclic-AMP phosphodiesterase activity
<i>RYR1</i>	0.418	6.04E-05	enables calcium ion binding and transport
<i>CACNG5</i>	0.825	2.04E-04	regulator of calcium ion transport and glutamatergic receptor activity

Figure 9. Ingenuity pathway analysis (IPA) identified canonical pathways regulated by APP/PS1 genotype and responsive to glyburide treatment. (A) Venn diagram representing pathways affected by 1) APP/PS1 genotype compared to wildtype controls, 2) glyburide treatment compared to placebo treatment in APP/PS1 mice, and 3) glyburide treated APP/PS1 mice compared wildtype controls. APP/PS1 genotype upregulated 53 pathways while glyburide treatment downregulated 18 pathways. Treatment with glyburide restored 3 pathways to wildtype levels. (B) Type II Diabetes Mellitus Signaling, $G\alpha_q$ Signaling, and Cardiac Hypertrophy Signaling Pathways were upregulated due to APP/PS1 genotype (red), downregulated due to glyburide treatment (blue), and indistinguishable from WT (gray). (C) Genes differentially expressed in Type II Diabetes Mellitus, $G\alpha_q$, and Cardiac Hypertrophy Signaling Pathways upregulated in APP/PS1 mice and subsequently reduced in glyburide treatment compared to placebo. (D) Of the genes identified in Fig 9c in mice, a subset of these genes are also altered in the human brain from AD patients. These genes are largely involved in calcium signaling and G-protein coupled signal transduction suggesting glyburide alters excitability within the brain.

A

C

B

Parameters	Wildtype-Placebo	APP/PS1-Placebo	APP/PS1-Glyburide
Heart rate (bpm)	433 ± 24	408 ± 9	447 ± 19
Stroke Volume (uL)	47 ± 3	49 ± 3	46 ± 3
Ejection Fraction (%)	69 ± 3	66 ± 6	72 ± 4
Fractional Shortening (%)	39 ± 2	37 ± 4	41 ± 3
Cardiac Output (mL/min)	21 ± 2	20 ± 2	21 ± 2
Left Ventricular Posterior Wall Thickness diastole (mm)	0.94 ± 0.08	0.85 ± 0.04	0.79 ± 0.02
E/e' ratio	28 ± 4	27 ± 1	28 ± 3

Figure 10. Cardiac function and arterial stiffness in wildtype and APP/PS1 mice following glyburide treatment. (A) Sample image of Color Doppler and B-mode modality used to assess pulse wave velocity. (B) Cardiac function was comparable between wildtype-placebo, APP/PS1-placebo and APP/PS1-glyburide treated mice on all metrics assessed (n=5-7 mice/group). (C) Pulse wave velocity, a metric of arterial stiffness, was assessed in wildtype-placebo, APP/PS1-placebo and APP/PS1-glyburide treated mice. APP/PS1 mice had a trend towards higher arterial stiffness compared to wildtype. Short term treatment with glyburide decreased arterial stiffness in APP/PS1 mice. Significance determined by one-way ANOVA with Tukey's test. p values reported to demonstrate trends (p<0.1).

Figure 11. Glyburide treatment improved learning and memory in APP/PS1 mice. (A) Both placebo and glyburide groups demonstrated the ability to learn on the Morris Water Maze (MWM) test by decreasing latency to platform over consecutive testing days ($p < 0.0001$; $n = 8$ mice/group). (B) Both placebo and glyburide groups spent more time in target quadrant during probe trial ($p < 0.004$). (C) Glyburide treated APP/PS1 mice had increased platform crossings ($p < 0.06$) compared to placebo treated controls, suggesting improved learning and memory. (D) No change in functional connectivity was found in the cingulate (Cing), motor (Motor), somatosensory (SS), retrosplenial (RS), and visual (Vis) cortices either due to disease or treatment ($n = 5-7$ mice/group). Significance determined by two-way ANOVA with Tukey's test. p values reported to demonstrate trends.

Figure 12. K_{ATP} channel inhibition with systemic glyburide reduces Aβ pathology and vascular damage. Increased Aβ oligomers and amyloid plaques contribute to vascular damage in AD. This coincides with increased expression of vascular K_{ATP} channels in the AD brain, which are important modulators of vasoreactivity. We demonstrate that peripheral treatment with the sulfonylurea and K_{ATP} channel inhibitor, glyburide, reduced the aggregation and activity-dependent production of Aβ. Our data suggest that glyburide targets vascular K_{ATP} channel activity to reduce arterial stiffness, improve vasoreactivity, and normalize pericyte-endothelial cell morphology, providing evidence that vascular K_{ATP} channels are an important, targetable component of Alzheimer's related pathology.